Archives of Clinical Infectious Diseases
Infectious Diseases and Tropical Medicine Research Center, SBUMS
To evaluate the strength of association and to determine the best prediction of response in terms of sensitivity and specificity among quantitative baseline HBV-DNA levels in blood serum in patients with chronic hepatitis B (CHB) infection who treated with interferon-alpha-2b.
Totally, 78 CHB patients with serum HBV-DNA>105 copies/mL were treated with interferonalpha- 2b (PDferon: Pooyesh Darou, Tehran, Iran) for 52 weeks as 5 MU Sc. for 24 weeks in HBeAg(+) and 48 weeks for HBeAg(-) at baseline of study in Tehran, Iran. Serum HBV-DNA level using Cobas Amplicor HBV Monitor test and HBeAg status were assessed at baseline and end of 6-months follow-up. Sustained response (SR) (n=42, 56%) was defined by HBeAg seroconversion (n=12), or with a decrease in HBV-DNA >105 copies/mL to undetectable value (n=33), or chemical response (n=20).
Higher pretreatment HBV-DNA levels have a significant relationship with better response to treatment in HBeAg (+) (R=0.7, p=0.04). Positivity of HBeAg in SR was a better predictor of chemical response in our patients, when compared to HBeAg negative (SR: 85% vs. 15%, respectively). At end of follow up, HBeAg (-) patients revealed more decrease in HBV-DNA levels than HBeAg (+) (412 vs. 290 105 copies/ml, p<0.05). Sensitivity of HBV-DNA in HBeAg (+) was more than HBeAg(-) (75% vs. 62%), but specificity was less in HBeAg(+) (58% vs. 45%). Area under ROC was 0.63 in HBeAg (-).
Higher pretreatment HBV-DNA levels have a significant relationship with better response to treatment in HBeAg positive patients of CHB. Although HBV-DNA in HBeAg negative was decreased significantly from baseline to end of follow-up, monitoring with sensitive quantitative baseline HBV-DNA measurement in these patients was not a better predictor of SR than HBeAg positive.
© 2011, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Keshvari M, Alavian SM, Sharafi H, Karimi G, Gholami Fesharaki M. Interferon Alpha-2b Therapy in Chronic Hepatitis Delta. Hepat Mon. 2014;14(3):e15729. doi: https://doi.org/10.5812/hepatmon.15729
Mohamadkhani A, Besharat S, Gol-Jah Rad G, Pour Dadash Asiabar A, Roshandel G, et al. Higher Serum Levels of Type I Interferon Receptor in Adults with Chronic Hepatitis B Leading to Hepatitis B Surface Antigen Clearance. Jundishapur J Microbiol. 2017;10(3):e41319. doi: https://doi.org/10.5812/jjm.41319
Guo Y, Zhu Y, Chen A, Zhou M, Li Z, et al. Hepatitis B Virus Genotype B and High Expression of Interferon Alpha Receptor ? Subunit are Associated With Better Response to Pegylated Interferon Alpha 2a in Chinese Patients With Chronic Hepatitis B Infection. Hepat Mon. 2012;12(5):. doi: https://doi.org/10.5812/hepatmon.6173
Chen J, Lai S, Zheng M. Efficacy Analysis and Influencing Factors of HBsAg Response in Chronic Hepatitis B Patients Treated with Nucleoside Analogues and Pegylated Interferon Sequential Therapy with High HBsAg Levels. Hepat Mon. 2025;25(1):e165180. doi: https://doi.org/10.5812/hepatmon-165180
Bahcecioglu IH, Ispiroglu M, Demirel U, Yalniz M. Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience. Hepat Mon. 2015;15(3):e24366. doi: https://doi.org/10.5812/hepatmon.24366
More by these authors
Last Update: 1 month ago
Last Update: 1 month ago
Last Update: 1 month ago
Last Update: 1 day ago
Last Update: 2 days ago
Last Update: 5 days ago
